Listen & Subscribe

Get The Latest FutureTech Podcast News Delivered Right To Your Inbox

There are about 90 million dogs in the U.S. right now, which means it’s almost guaranteed that you either have one or know someone who does. They’re known as man’s best friend, and most of us would do anything to help give them the longest and healthiest lives possible. Nonetheless, half of them will die of cancer after reaching age 10.

On today’s episode, founder and CEO of LEAH Labs, Wesley Wierson, explains CAR T-cell therapy, a recently FDA-approved therapy for leukemia and lymphoma in humans that harnesses the power of the immune system to attack cancer cells. He also describes how implementing this therapy in dogs could simultaneously benefit dogs and humans suffering from the same type of cancer.

“LEAH Labs was founded to bring self-therapies to dogs,” says Wierson, as he goes on to explain how testing this therapy in dogs will provide humans with a much greater understanding as to how the therapy works and what causes CAR T-cell toxicity in both humans and dogs—a major drawback of the therapy. Wierson explains why the current method of CAR T-cell therapy development is not only insufficient and inaccessible, but potentially misinformed, and how the work being done at LEAH Labs is completely revolutionizing this.

Interested in learning more? Press play and check out

Accessibility Close Menu
Accessibility menu Accessibility menu Accessibility menu
× Accessibility Menu CTRL+U